11. The use according to claim 8, wherein the PF4 interacting heparinoid is at least 85%, 90%, or 95% desulfated at each of the 2-O and 3-O positions.

12. The use according to any of the preceding claims, wherein the PF4-interacting heparinoid has an average molecular weight of about 8 kDa to about 15 kDa, about 11 kDa to about 14 kDa, or about 11 kDa to about 13 kDa.

13. The use according to claim 12, wherein the PF4-interacting heparinoid is a heparinoid that is substantially desulfated at 2-O and 3-O positions (ODSH).

14. The use according to any of the preceding claims, wherein the medicament is for subcutaneous administration.

15. The use according to any of the preceding claims, wherein the medicament is for administration intravenously.

16. The use according to claim 15, wherein the medicament is for administration as one or more bolus injections.

17. The use according to claim 16, wherein the one or more bolus injections are administered at a dose of about 1 mg/kg to about 25 mg/kg, about 1 mg/kg to about 10 mg/kg, about 1 mg/kg to about 5 mg/kg, or about 2 mg/kg to about 4 mg/kg.

18. The use according to any of the preceding claims, wherein the medicament is for administration concurrently, sequentially, and/or separately with the myelosuppressive treatment regimen.

19. The use according to any of the preceding claims, wherein the subject has been diagnosed with cancer.

20. The use according to claim 19, wherein the cancer is acute myelogenous leukemia (AML) and the anti-neoplastic myelosuppressive treatment regimen is a regimen suitable for treating the acute myelogenous leukemia (AML).

11. ~~The use according to claim 8, wherein the PF4-interacting heparinoid is at least 85%,~~ 90%, or 95% desulfated at each of the 2-O and 3-O positions.

12. The use according to any of the preceding claims, wherein the PF4-interacting heparinoid has an average molecular weight of about 8 kDa to about 15 kDa, about 11 kDa to about 14 kDa, or about 11 kDa to about 13 kDa.

13. The use according to claim 12, wherein the PF4-interacting heparinoid is a heparinoid that is substantially desulfated at 2-0 and 3-0 positions (ODSH).

14. The use according to any of the preceding claims, wherein the medicament is for subcutaneous administration.

15. The use according to any of the preceding claims, wherein the medicament is for administration intravenously.

16. The use according to claim-15, wherein the medicament is for administration as one or more bolus injections.

17. The use according to claim 16, wherein the one or more bolus injections are administered at a dose of about 1 mg/kg to about 25 mg/kg, about 1 mg/kg to about 10 mg/kg, about 1 mg/kg to about 5 mg/kg, or about 2 mg/kg to about 4 mg/kg.

18. The use according to any of the preceding claims, wherein the medicament is for administration concurrently, sequentially, and/or separately with the myelosuppressive treatment regimen.

19. The use according to any of the preceding claims, wherein the subject has been diagnosed with cancer.

20. The use according to claim 20, wherein the cancer is acute myelogenous leukemia (AML) and the anti-neoplastic myelosuppressive treatment regimen is a regimen suitable for treating the acute myelogenous leukemia (AML).